Cytokines in Parkinson’s disease

  • T. Nagatsu
  • M. Mogi
  • H. Ichinose
  • A. Togari
Conference paper


We found that in Parkinson’s disease (PD) the levels of various cytokines [tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-2, IL-4, IL-6, epidermal growth factor (EGF), transforming growth factor (TGF)-α, TGF-β1] were significantly increased in the striatum (caudate and putamen) of the postmortem brain and in ventricular or spinal cerebrospinal fluid (VCSF, LCSF). Furthermore, the levels of the apoptosis-related proteins such as bcl-2 and soluble Fas (sFas) in the striatum were also elevated in PD. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated parkinsonism mice, the levels of IL-1β in the striatum were significantly increased, but those of nerve growth factor (NGF) were significantly decreased, compared with control mice. In hemiparkinsonism rats produced by injection of 6-hydroxydopamine (6-OHDA) into one side of the median forebrain bundle, the levels of TNF-α in the 6-OHDA-treated side were increased in the striatum and substantia nigra, but not in the cerebral cortex, compared with those in the control side. Repeated administration of L-DOPA in the 6-OHDA-treated rats did not change the TNF-α levels in the control side and in the 6-OHDA-treated side in the substantia nigra, striatum, and cerebral cortex.

Our results suggest that the changes in the levels of cytokines, neurotrophins, and apoptosis-related proteins in the nigrostriatal regions of PD may be involved in apoptosis and degeneration of the nigrostriatal DA neurons.


Nerve Growth Factor Substantia Nigra Median Forebrain Bundle Control Side Nerve Growth Factor Level 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Blum-Degen D, Muller T, Kuhn W, Gerlach M, Przuntek H, Riederer P (1995) Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer’s and de novo Parkinson’s disease patients. Neurosci Lett 202: 17–20PubMedCrossRefGoogle Scholar
  2. Boka G, Anglade P, Wallach D, Javoy-Agid F, Agid Y, Hirsch EC (1994) Immunohistochemical analysis of tumor necrosis factor and its receptors in Parkinson’s disease. Neurosci Lett 172: 151–154PubMedCrossRefGoogle Scholar
  3. Imaoka T, Date I, Ohmoto T, Nagatsu T (1998) Significant behavioral recovery in Parkinson’s disease model by direct intracerebral gene transfer using continuous injection of a plasmid DNA-liposome complex. Hum Gene Ther 9: 1093–1102PubMedCrossRefGoogle Scholar
  4. Marshall K.A., Daniel S.E., Cairns N, Jenner P, Halliwell B (1997) Upregulation of the antiapoptotic protein Bcl-2 may be an early event in neurodegeneration studies: on Parkinson’s and incidental Lewy body disease. Biochem Biophys Res Commun 240:84–87PubMedCrossRefGoogle Scholar
  5. Matsuura K, Makino H, Ogawa N (1997) Cyclosporin A attenuates the decrease in tyrosine hydroxylase immunoreactivity in nigrostriatal dopaminergic neurons and in striatal dopamine content in rats with intrastriatal injection of 6-hydroxydopamine. Exp Neurol 146: 526–535PubMedCrossRefGoogle Scholar
  6. McGeer P.L., McGeer E.G. (1995) The inflammatory response system of brain, implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev 21:195–218PubMedCrossRefGoogle Scholar
  7. McGeer P.L., Itagaki S, Boyes B.E., McGeer E.G. (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology 38: 1285–1291PubMedCrossRefGoogle Scholar
  8. Mochizuki H, Goto K, Mori H, Mizuno Y (1996) Histochemical detection of apoptosis in Parkinson’s disease. J Neurol Sci 137: 120–123PubMedCrossRefGoogle Scholar
  9. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T (1994a) Tumor necrosis factor-α (TNF-α) increases both in the brain and cerebrospinal fluid from parkinsonian patients. Neurosci Lett 165: 208–210PubMedCrossRefGoogle Scholar
  10. Mogi M, Harada M, Kondo T, Riederer P, Inagaki H, Minami M, Nagatsu T (1994b) Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-β are elevated in the brain from parkinsonian patients. Neurosci Lett 180: 147–150Google Scholar
  11. Mogi M, Harada M, Kondo T, Narabayashi H, Riederer P, Nagatsu T (1995a) Transforming growth factor-β1 lavels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson’s disease. Neurosci Lett 193: 129–132PubMedCrossRefGoogle Scholar
  12. Mogi M, Harada M, Kondo T, Riederer P, Nagatsu T (1995b) Brain β2-microglobulin levels are elevated in the striatum in Parkinson’s disease. J Neural Transm [P-D Seet] 9: 87–92CrossRefGoogle Scholar
  13. Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M, Nagatsu T (1996a) Interleukin (IL)-1β, IL-2, IL-4, IL-6, and transforming growth factor-β levels are elevated in ventricular cerebrospinal fluid of juvenile parkinsonism and Parkinson’s disease. Neurosci Lett 193: 129–132CrossRefGoogle Scholar
  14. Mogi M, Harada M, Kondo T, Mizuno Y, Riederer P, Nagatsu T (1996b) Bcl-2 protein is increased in the brain from parkinsonian patients. Neurosci Lett 215: 137–139PubMedGoogle Scholar
  15. Mogi M, Harada M, Kondo T, Narabayashi H, Riederer P, Nagatsu T (1996c) Interleukin-2 but not basic fibroblast growth factor is elevated in parkinsonian brain. J Neural Transm 103: 1077–1081PubMedCrossRefGoogle Scholar
  16. Mogi M, Harada M, Kondo T, Mizuno Y, Riederer P, Nagatsu T (1996d) The soluble form of Fas molecule is elevated in parkinsonian brain tissues. Neurosci Lett 220:195–198PubMedCrossRefGoogle Scholar
  17. Mogi M, Togari A, Ogawa M, Ikeguchi K, Shimazu N, Fan D-S, Nakano I, Nagatsu T (1998) Effects of systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydrophridine (MPTP) to mice on interleukin-1β and nerve growth factor in the striatum. Neurosci Lett 250: 25–28PubMedCrossRefGoogle Scholar
  18. Mogi M, Togari A, Tanaka K, Ogawa N, Ichinose H, Nagatsu T (1999a) Increase in level of tumor necrosis factor (TNF)-α in 6-hydroxydopamine-lesioned striatum in rats without influence of systemic L-DOPA on the TNF-α induction. Neurosci Lett 268:101–104PubMedCrossRefGoogle Scholar
  19. Mogi M, Togari A, Kondo T, Mizuno Y, Komure O, Kuno S, Ichinose H, Nagatsu T (1999b) Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson’s disease. Neurosci Left 270: 45–48CrossRefGoogle Scholar
  20. Nagatsu T, Mogi M (1998) Cytokines in Parkinson’s disease. In: Fisher A, Hanin I, Yoshida M (eds) Progress in Alzheimer’s and Parkinson’s diseases. Plenum, New York, pp 407–412 (Adv Behav BiolGoogle Scholar
  21. Scott S.A., Mufson E.J., Weingartner J.A., Skau K.A., Crutcher K.A. (1995) Nerve growth factor in Alzheimer’s disease: increased levels throughout the brain coupled with declines in nucleus basalis. J Neurosci 15: 6213–6221PubMedGoogle Scholar
  22. Temlett J.A. (1996) Parkinson’s disease: biology and etiology. Curr Opin Neurobiol 9: 303–307CrossRefGoogle Scholar
  23. Vawter M.P., Dillon-Carter O, Tourtellotte W.W., Carvey P, Freed W (1996) TGFBI and TGFβ2 concentrations are elevated in Parkinson’s disease in ventricular cerebrospinal fluid. Exp Neurol 142: 313–322PubMedCrossRefGoogle Scholar
  24. Walkinshaw G, Waters C.M. (1995) Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson’s disease. J Clin Invest 95:2458–2464PubMedCrossRefGoogle Scholar
  25. Ziv I, Zilkha-Falb R, Offen D, Shirvan A, Barzilai A, Melamed E (1997) Levodopa induces apoptosis in cultured neuronal cells, a possible accelerator of nigrostriatal degeneration of Parkinson’s disease? Mov Disord 12: 17–23PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 2000

Authors and Affiliations

  • T. Nagatsu
    • 1
  • M. Mogi
    • 2
  • H. Ichinose
    • 1
  • A. Togari
    • 2
  1. 1.Institute for Comprehensive Medical ScienceFujita Health UniversityToyoake, AichiJapan
  2. 2.Department of Pharmacology School of DensityAichi-Gakuin UniversityNagoyaJapan

Personalised recommendations